Cerecor Inc. (NASDAQ:CERC) traded at a new 52-week high today of $4.50. So far today approximately 744,000 shares have been exchanged, as compared to an average 30-day volume of 1.4 million shares.
Cerecor Inc. (NASDAQ:CERC) is currently priced 59.2% above its average consensus analyst price target of $1.74.
In the past 52 weeks, shares of Cerecor Inc. have traded between a low of $1.52 and a high of $4.50 and is now at $4.25, which is 180% above that low price.
Cerecor Inc is a biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a robust pipeline of innovative therapies in neurology, pediatric healthcare, and orphan rare diseases. The Company is also developing three other neurological clinical and preclinical stage compounds. The Company’s pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. The Company also markets prescription drugs that treat a range of pediatric diseases, disorders and conditions. Cerecor’s prescription drugs include Millipred, Ulesfia, Karbinal ER, AcipHex Sprinkle and Cefaclor for Oral Suspension. The Company has marketed medical device, Flexichamber.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer